FBT ETF launched 19 years ago and has delivered exceptional returns compared to the broader Health Care sector. Read why FBT ...

He was talking about the biotechnology company ImmunityBio. EF Hutton analyst Jason Kolbert initiated coverage of ImmunityBio ...

reflects the changing nature of the biotech’s relationship with Vertex regarding Casgevy. The outlook may be improving as CRISPR’s stock has gained 30% from the lows it hit earlier this ...

The cyclical, high-risk, high-reward nature of the biotech industry is on full display in 2024. This industry is centered on using living organisms and bioprocesses for innovative drug development ...